CRISPR Therapeutics CRSP Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -15,754.2%— | -18,933.6%— | -1,498.3%— | —— | —— | |
| Net margin | -13,856.5%— | -16,569.8%— | -1,273.7%— | —— | —— | |
| EBITDA margin | -15,289.6%— | -18,378.7%— | -1,449.6%— | —— | —— | |
| Free cash flow margin | -9,777.6%-8,960pp | -9,855.5%-9,468pp | -790.7%-696pp | -855.6%-793pp | -817.1%-756pp | |
| Returns | ||||||
| Return on equity | -31.2%— | -30.2%— | -25.3%— | —— | —— | |
| Return on assets | -23.2%— | -25.8%— | -21.7%— | —— | —— | |
| Return on invested capital | -32.4%— | -36.5%— | -30.4%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×-0.1× | 0×-0.1× | 0×-0.1× | |
| Liquidity | ||||||
| Current ratio | 18×+2.3× | 13.3×-8.8× | 16.2×-5.4× | 16.6×+0.9× | 15.6×-2.2× | |
| Quick ratio | 18×+2.3× | 13.3×-8.8× | 16.2×-5.4× | 16.6×+0.9× | 15.6×-2.2× | |
| Cash ratio | 3.1×+1.1× | 2.3×-1.1× | 2.4×-0.1× | 1.9×-1.9× | 2×-4.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×+0.3× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.3×+0.2× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $18.89-11.2% | $21.37-6.7% | $20.98-7.8% | $19.65-15.8% | $21.28-16.5% | |
| Valuation | ||||||
| Market capitalization | $4.57B+56.4% | $5B+48.8% | $5.89B+47.3% | $4.04B-11.9% | $2.92B-46.7% | |
| Enterprise value | $4.93B+69.8% | $4.86B+47.8% | $5.82B+45.4% | $4.06B-6.3% | $2.9B-41.9% | |
| Price / sales | 1,112.8×+1,035× | 1,423.8×+1,334× | 153.8×+134× | 106.2×+83.5× | 77.5×+57.3× | |
| Price / book | 2.5×+0.9× | 2.6×+0.9× | 3.1×+1.0× | 2.4×0.0× | 1.6×-1.0× | |
| EV / sales | 1,201.6×+1,125× | 1,383.7×+1,296× | 151.8×+132× | 106.8×+85.3× | 77.1×+58.7× | |
| Free cash flow yield | -8.8%+1.8pp | -6.9%-2.6pp | -5.1%-0.4pp | -8.1%-5.3pp | -10.5%-7.5pp | |
| Earnings yield | -12.5%— | -11.6%— | -8.3%— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do CRISPR Therapeutics's ratios come from?
- Every ratio is computed from CRISPR Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
